Positive effective results were first observed in studies investigating the use of alemtuzumab (monoclonal antibody-CD52) in CLL patients with poor prognostic features including TP53 disruptions (Lozanski et al., 2004; Pettitt et al., 2012). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.